Header Logo

Search Results (56)

A preclinical approach for gene therapy of beta-thalassemia.Academic Article Why?
Decreased differentiation of erythroid cells exacerbates ineffective erythropoiesis in beta-thalassemia.Academic Article Why?
Gene Therapy in Global Health: Meeting the Needs of Chinese Patients with Beta-Thalassemia.Academic Article Why?
Hepcidin and Hfe in iron overload in beta-thalassemia.Academic Article Why?
Low bone mineral density in adolescents with beta-thalassemia.Academic Article Why?
Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy.Academic Article Why?
Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia.Academic Article Why?
Characterization of a spontaneous mutation to a beta-thalassemia allele.Academic Article Why?
beta-ThalassemiaConcept Why?
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.Academic Article Why?
Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols.Academic Article Why?
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial.Academic Article Why?
Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.Academic Article Why?
Wolfe, ScotPerson Why?
Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in beta-thalassemia.Academic Article Why?
Per Page    Page  of 4last Nextnext
Search Criteria
  • beta Thalassemia
Filter by Type
Click "Why?" to see why an item matched the search.